Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer

Urology

Volumn 67, Issue 5, 2006, Pages 1007-1011

  Jani, Ashesh B ^a,b   Feinstein, Jeffrey M ^a,b   Pasciak, Robert ^b   Krengel, Samuel ^b   Weichselbaum, Ralph R ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b Adventist Hinsdale Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN; PALLADIUM; RADIOACTIVE IODINE; RADIOISOTOPE; TUMOR MARKER;

AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMICAL ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LOG RANK TEST; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; PROSTATE TUMOR; RETROSPECTIVE STUDY; SURVIVAL;

AGED; BRACHYTHERAPY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646852211     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.11.008     Document Type: Article

References (26)

1. Peschel R.E., and Colberg J.W. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4 (2003) 233-241
2. Jani A.B., and Hellman S. Early prostate cancer. clinical decision-making. Lancet 361 (2003) 1045-1053
3. Martinez A.A., Pataki I., Edmundson G., et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer. a feasibility report. Int J Radiat Oncol Biol Phys 49 (2001) 61-69
4. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
5. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
6. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer. a multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
7. Blasko J.C., Ragde H., Grimm P.D., et al. Prostate brachytherapy. importance of technique. J Clin Oncol 14 (1996) 1965-1967
8. Merrick G.S., Butler W.M., Lief J.H., et al. Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 8 (2002) 322-327
9. Critz F.A., Williams W.H., Levinson A.K., et al. Simultaneous irradiation for prostate cancer. intermediate results with modern techniques. J Urol 164 3 Pt 1 (2000) 738-741
10. Blasko J.C., Grimm P.D., Sylvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
11. Potters L., Fearn P., and Kattan M. The role of external radiotherapy in patients treated with permanent prostate brachytherapy. Prostate Cancer Prostatic Dis 5 (2002) 47-53
12. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
14. Cancer and Leukemia Group B (CALGB): Protocol 99809-phase II trial of androgen suppression for 6 months combined with external beam radiotherapy (EBRT) with a brachytherapy (BT) boost for patients with intermediate-risk prostate cancer. Available at: www.calgb.org. Accessed October 4, 2005.
15. Radiation Therapy Oncology Group (RTOG): Protocol 98-05: phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. Available at: www.rtog.org. Accessed October 4, 2005.
16. Radiation Therapy Oncology Group (RTOG): Protocol P-0019: a phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Available at: www.rtog.org. Accessed October 4, 2005.
17. Radiation Therapy Oncology Group (RTOG): Protocol 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma. Available at: www.rtog.org. Accessed October 4, 2005.
18. Saw C.B., Meigooni A.S., and Nath R. the American Association of Physicists in Medicine: Review of AAPM Task Group No. 43 recommendations on interstitial brachytherapy sources dosimetry. Med Dosim 23 (1998) 259-263
19. 103Pd interstitial source calibration and dosimetry. implications for dose specification and prescription. Med Phys 27 (2000) 634-642
20. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate. techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 12 (2002) 81-94
21. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
22. Fleming T.R., and Lin D.Y. Survival analysis in clinical trials. past developments and future directions. Biometrics 56 (2000) 971-983
23. Dawson-Saunders B., and Trapp R.G. Basic and Clinical Biostatistics (1990), Prentice Hall, East Norwalk, Connecticut
24. Jani A.B., Hand C.M., Lujan A.E., et al. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim 29 (2004) 42-48
25. Ghaly M., Wallner K., Merrick G., et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity. morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 55 (2003) 1288-1293
26. Corriveau J., Wallner K., Merrick G., et al. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Brachytherapy 2 (2003) 108-113